| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.ajantapharma.com | |
| Market Cap | 26,945.95 Cr. | |
| Enterprise Value(EV) | 26,684.09 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 58.43 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | 36.63 | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.30 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 293.20 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 7.30 | Calculated using Price: 2,140.00 |
| Dividend Yield | 0.33 | Period Ending 2023-03 |
| No. of Shares Subscribed | 12.59 Cr. | 125,915,655 Shares |
| FaceValue | 2 | |
| About Ajanta Pharma Ltd. | ||
| Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Its business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. Emerging markets are the major contributors in company's branded generic business where it is present across Asia and Africa. It has designed customised basket of products for each of these markets and serve wide range of therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. | ||
| 1 Day |
|
+0.34% |
| 1 Week |
|
+3.68% |
| 1 Month |
|
-0.53% |
| 3 Month |
|
-2.48% |
| 6 Month |
|
+24.06% |
| 1 Year |
|
+66.31% |
| 2 Year |
|
+81.45% |
| 5 Year |
|
+213.82% |
| 10 Year |
|
+699.01% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 43.24 | 40.93 | 36.77 | 26 | 18.07 | 19.32 | 23.38 | 22.77 | 17.68 | |
| Return on Capital Employed (%) | 56.43 | 51.59 | 45.72 | 34.49 | 23.84 | 27.44 | 32.2 | 29.37 | 22.57 | |
| Return on Assets (%) | 29.57 | 31.66 | 30.69 | 22.06 | 14.52 | 14.44 | 17.03 | 17.16 | 13.21 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 841 | 1,191 | 1,568 | 2,041 | 2,245 | 2,599 | 2,996 | 3,264 | 3,388 | 3,482 | |
| Non Curr. Liab. | 56 | 29 | 9 | 39 | 162 | 228 | 275 | 285 | 177 | 18 | |
| Curr. Liab. | 250 | 260 | 247 | 346 | 498 | 746 | 839 | 647 | 1,139 | 799 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 1,146 | 1,479 | 1,823 | 2,426 | 2,906 | 3,572 | 4,109 | 4,197 | 4,705 | 4,299 | |
| Non Curr. Assets | 513 | 716 | 973 | 1,202 | 1,605 | 1,791 | 1,891 | 1,932 | 1,871 | 1,737 | |
| Curr. Assets | 633 | 763 | 851 | 1,224 | 1,301 | 1,781 | 2,218 | 2,264 | 2,825 | 2,563 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 1,146 | 1,479 | 1,823 | 2,426 | 2,906 | 3,572 | 4,109 | 4,197 | 4,705 | 4,299 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 1,474 | 1,734 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,036 | |
| Other Income | 17 | 21 | 24 | 24 | 21 | 92 | 26 | 116 | 99 | 104 | |
| Total Income | 1,490 | 1,755 | 2,007 | 2,150 | 2,076 | 2,680 | 2,916 | 3,457 | 3,841 | 4,140 | |
| Total Expenditure | -968 | -1,147 | -1,296 | -1,467 | -1,489 | -1,905 | -1,891 | -2,412 | -2,959 | -3,011 | |
| PBIDT | 522 | 608 | 711 | 683 | 588 | 776 | 1,025 | 1,045 | 882 | 1,129 | |
| Interest | -6 | -5 | -1 | 0 | -1 | -12 | -8 | -10 | -6 | -7 | |
| Depreciation | -52 | -44 | -61 | -60 | -72 | -96 | -116 | -125 | -131 | -134 | |
| Taxation | -146 | -143 | -141 | -154 | -127 | -196 | -246 | -197 | -157 | -252 | |
| Exceptional Items | -8 | -4 | |||||||||
| PAT | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 736 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 310 | 416 | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 736 | |
| Adjusted EPS | 23 | 31 | 38 | 36 | 30 | 36 | 50 | 56 | 47 | 58 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 212 | 279 | 326 | 609 | 281 | 375 | 457 | 576 | 562 | 792 | |
| Cash Fr. Inv. | -188 | -158 | -209 | -383 | -256 | -223 | -224 | -282 | -74 | -560 | |
| Cash Fr. Finan. | -20 | -105 | -117 | -202 | 0 | -147 | -129 | -318 | -460 | -108 | |
| Net Change | 4 | 16 | 0 | 24 | 25 | 4 | 104 | -24 | 28 | 124 | |
| Cash & Cash Eqvt | 39 | 54 | 41 | 66 | 91 | 95 | 199 | 178 | 205 | 331 |
|
Tue, 23 Apr 2024
Analysts/Institutional Investor Meet/Con. Call Updates Ajanta Pharma Limited has informed the Exchange about Schedule of meet |
|
Mon, 22 Apr 2024
Board Meeting Intimation AJANTA PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 02-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Other business. |
|
Mon, 15 Apr 2024
Disclosure under SEBI Takeover Regulations ￂﾠYOGESH M. AGRAWALￂﾠhas Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of Indiaￂﾠ(Substantial Acquisition of Shares and Takeovers) Regulations, 2011.ￂﾠ |
| Wed, 24 Apr 2024 |
High Delivery Percentage
|
Close Within 52 Week High Zone
|
High Increase in 6 Months
|
High Increase in 1 Year
|
High Increase in 2 Years
|
